Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus, treated with Lantus±SU; ≥5-year after diagnosis~* Aged 20-75 years~* Hemoglobin A1C ≥7.0%-≤10.0%~* Fasting plasma glucose ≤180 mg/dL at screening~* Stable treatment (±20%) with Lantus for 3 months or more prior to screening.~* Sulfonylurea dose stable for 3 months or more prior to screening~Exclusion criteria:~* Type 1 diabetes mellitus~* Pregnancy or lactation~* Hypersensitivity to Lixisenatide~* Severely uncontrolled glycemic situation~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery or inflammatory bowel disease~* History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening~* History within the previous 6 months of myocardial infarction, stroke or heart failure requiring hospitalization or drug or alcohol abuse~* Uncontrolled/inadequately controlled hypertension at the time of screening, with a resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>95 mmHg~* Amylase and/or lipase \>3 times or aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (ALP) \>2 times the upper limit of the normal laboratory range~* End-stage renal disease and/or dialysis and clinically relevant history of gastrointestinal disease~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen.
- Sitagliptin - Januvia (Type: ACTIVE_COMPARATOR): 50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).